This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection (NCT05763576), a randomized phase 1 study. The primary outcome is Part 1a: Number of Healthy Volunteers With Adverse Events (AEs) and Serious Adverse Events (SAEs).
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT05763576 |
| Phase | Phase 1 |
| Condition | Chronic Hepatitis B |
| Allocation | Randomized |
| Design model | Sequential |
| Masking | Double |
| Enrollment | 60 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Hoffmann-La Roche |
| Results posted | Yes |
2. Clinical Question
Population
The study included healthy participants and participants with chronic hepatitis B virus infection. Its primary safety endpoint concerned healthy volunteers in Part 1a. The brief summary describes participants with chronic hepatitis B as virologically suppressed. The registry record lists chronic hepatitis B as the condition and gives a planned enrollment figure of 60.
Intervention
The investigational drug was RO7565020. The study description identifies it as a first-in-human dose-finding and dose-escalation study, with single and/or multiple doses in healthy participants and/or participants with chronic hepatitis B. The registry also lists nucleos(t)ide analogue treatment among the interventions, but does not report its specific role in each group.
Comparator
Placebo is listed as an intervention, and the adverse-event record includes a Part 1a placebo group. The record does not provide detailed arm descriptions, so the exact treatment assignment and comparison structure for each cohort is not reported in the registry record.
Primary question
The primary endpoint asks how many healthy volunteers in Part 1a experienced adverse events (AEs) or serious adverse events (SAEs) during follow-up of up to approximately 40 weeks. This is a descriptive safety question. The registry does not present a single inferential comparison for the endpoint, and the record does not report a formal estimate of a treatment difference.
The study’s stated objectives also include characterizing pharmacokinetics and pharmacodynamics, alongside safety and tolerability. The listed secondary outcomes concern measures such as concentration timing, maximum concentration, exposure over time, terminal half-life, distribution volume, and clearance. Those objectives indicate that the study was designed to describe how the drug behaves and to examine biological effects, but the posted record does not include numerical results for those measures.
3. Trial Design
This was a Phase I, randomized, double-masked, sequential study of RO7565020. The registry describes it as first-in-human, multicenter, dose-finding, and dose-escalation research. The brief summary says the study was intended to investigate safety and tolerability and characterize pharmacokinetics and pharmacodynamics after single and/or multiple doses. It involved healthy participants and/or virologically suppressed participants with chronic hepatitis B virus infection.
The registry lists RO7565020, placebo, and nucleos(t)ide analogue treatment as interventions. Placebo and RO7565020 also appear in the adverse-event groups, including a Part 1a placebo group and dose cohorts in Parts 1a and 2a. Detailed descriptions of the treatment assigned to each cohort are not reported in the registry record. The record therefore does not support reconstructing the dose sequence, the cohort-specific regimen, or the precise comparisons intended within each part.
The registry lists enrollment of 60. The record does not establish from that figure how many participants were randomized, treated, or included in each endpoint analysis. For the primary safety endpoint, the defined population includes randomized or assigned participants who received at least one dose of study treatment, whether they later withdrew or not. This is narrower than simply counting everyone enrolled.
The study status is terminated. The registry lists a start date of 2023-04-28 and a primary completion date of 2024-12-23. The reason for termination is not reported in the registry record, and termination alone does not explain whether the study stopped for safety, operational, scientific, or other reasons. The record also does not report a detailed protocol schedule or the planned number and timing of dose-escalation steps.
Although the study is randomized and double-masked, those design labels do not by themselves establish which groups can be compared for every outcome. The posted record does not provide detailed arm descriptions or a complete analysis plan. The primary endpoint is specifically framed around healthy volunteers in Part 1a, while the adverse-event listing also includes cohorts from Part 2a. These differences in scope matter when interpreting the counts.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: The study consists of 3 parts- Part 1a: single-ascending dose (SAD) and Part 1b: multiple doses in healthy participants, Part 2 (a and b): SAD in participants with CHB, and Part 3: multiple doses in participants with CHB. No participants were enrolled in the Part 1b, Part 2b, and Part 3 as the study was terminated by the sponsor.
Only the first 6 of 9 groups are shown.
Overall Study
| Stage | Part 1a Placebo | Part 1a Cohort 1 | Part 1a Cohort 2 | Part 1a Cohort 3 | Part 1a Cohort 4 | Part 1a Cohort 5 |
|---|---|---|---|---|---|---|
| STARTED | 12 | 6 | 6 | 6 | 6 | 6 |
| COMPLETED | 12 | 6 | 6 | 6 | 6 | 5 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 0 | 1 |
Reasons for not completing this period:
| Reason | Part 1a Placebo | Part 1a Cohort 1 | Part 1a Cohort 2 | Part 1a Cohort 3 | Part 1a Cohort 4 | Part 1a Cohort 5 |
|---|---|---|---|---|---|---|
| Study Terminated by Sponsor | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 1 |
Analysis population for the primary outcome, as defined in the registry: Safety population included all participants randomized/assigned to study treatment and who received at least one dose of the study treatment, whether prematurely withdrawn from the study or not.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
Population: Safety population included all participants randomized/assigned to study treatment and who received at least one dose of the study treatment, whether prematurely withdrawn from the study or not.
Only the first 6 of 10 groups are shown.
| Characteristic | Unit | Part 1a Placebo | Part 1a Cohort 1 | Part 1a Cohort 2 | Part 1a Cohort 3 | Part 1a Cohort 4 | Part 1a Cohort 5 |
|---|---|---|---|---|---|---|---|
| Participants analysed | 12 | 6 | 6 | 6 | 6 | 6 | |
| Age, Continuous | years | 34.2 (SD 9.3) | 39.8 (SD 7.9) | 34.8 (SD 12.4) | 47.3 (SD 8.6) | 39.0 (SD 13.1) | 38.5 (SD 11.2) |
| Sex: Female, Male: Female | Participants | 6 | 3 | 5 | 1 | 2 | 4 |
| Sex: Female, Male: Male | Participants | 6 | 3 | 1 | 5 | 4 | 2 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 1 | 0 | 0 | 0 | 0 | 1 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 11 | 5 | 6 | 6 | 6 | 5 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 0 | 1 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Asian | Participants | 4 | 0 | 1 | 1 | 2 | 1 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 1 | 0 | 1 | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 0 | 1 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): White | Participants | 4 | 5 | 4 | 5 | 3 | 4 |
| Race (NIH/OMB): More than one race | Participants | 2 | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 1 | 0 | 0 | 0 | 0 | 0 |
6. Primary Endpoint
The registry lists the primary outcome as Part 1a: Number of Healthy Volunteers With Adverse Events (AEs) and Serious Adverse Events (SAEs), measured over Up to approximately 40 weeks.
| Element | Registry entry |
|---|---|
| Result type | Count Of Participants |
| Measure of spread | not applicable |
| Unit | Participants |
| Endpoint classification | Binary Endpoint |
The primary endpoint counts healthy volunteers in Part 1a who experienced adverse events and serious adverse events. The stated observation period is up to approximately 40 weeks. An adverse event is defined broadly as an untoward medical occurrence after administration of a pharmaceutical product, whether or not it is considered related to that product. The definition includes an unfavorable or unintended sign, abnormal laboratory finding, symptom, or disease temporally associated with use of the medicinal product.
A serious adverse event is defined by its seriousness rather than by whether it is caused by treatment. The listed criteria include being fatal or life-threatening, requiring hospitalization or prolonging an existing hospitalization, causing persistent or significant disability or incapacity, involving a congenital anomaly or birth defect, being medically significant, or requiring intervention. Thus, an SAE count is not a count of events judged to be drug-related.
Counting participants with events is useful in an early-phase study because it gives a direct descriptive view of how many treated participants had events during the specified follow-up. It is not equivalent to counting every event: one participant could have more than one event, and a participant-level count does not describe event duration, severity beyond the SAE classification, or relationship to treatment. Those details are not reported in the registry record for the primary endpoint.
The registry defines the safety population as randomized or assigned participants who received at least one dose, including those who withdrew early. This definition identifies who was eligible for safety counting; it does not establish that every enrolled participant received treatment or contributed complete follow-up. Participant-level outcome details and the handling of incomplete observation are not reported in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The posted adverse-event figures are descriptive counts by named group. In Part 1a, the placebo group lists 12 participants at risk for SAEs, with 0 affected, and 12 at risk for other AEs, with 6 affected. Cohort 1 lists 6 participants at risk for each category, with 0 affected by SAEs and 4 affected by other AEs. Cohort 2 lists 6 at risk, with 0 affected by SAEs and 5 affected by other AEs. Cohort 3 lists 6 at risk, with 0 affected by SAEs and 4 affected by other AEs.
For the remaining Part 1a cohorts, Cohort 4 lists 6 participants at risk for each category, with 1 affected by an SAE and 6 affected by other AEs. Cohort 5 lists 6 at risk, with 0 affected by SAEs and 6 affected by other AEs. Cohort 6 lists 6 at risk, with 0 affected by SAEs and 1 affected by other AEs. In Part 2a, Cohort 1 lists 6 participants at risk, with 0 affected by SAEs and 2 affected by other AEs; Cohort 2 lists 6 at risk, with 0 affected by SAEs and 3 affected by other AEs. These are participant counts, not a measure of how many total events occurred.
The counts should be read in light of the study’s early-phase, sequential, dose-finding context. Cohort sizes in the listed groups are small, and the record does not describe the dose assigned to each cohort. A difference in counts between groups therefore cannot, by itself, establish a treatment effect or explain why counts differ. Nor does the presence of an event establish that the investigational drug caused it, since the event definition explicitly does not require a causal relationship.
The primary endpoint title concerns healthy volunteers in Part 1a, whereas the posted adverse-event groups include both Part 1a and Part 2a. The figures for Part 2a should not be treated as part of the primary endpoint without a specified analysis supporting that interpretation. The registry record does not provide a single adjusted or inferential comparison for the primary endpoint; it indicates that the endpoint has several categories or time points and was not reduced to one comparison.
No confidence intervals, p-values, or model-based estimates for these safety counts are reported in the registry record. Without such estimates, the figures describe the participants recorded with events but do not quantify the uncertainty around a comparative effect. The posted results also do not report pharmacokinetic or pharmacodynamic values, despite those being study objectives and the subject of listed secondary outcomes.
The figures can therefore be read as a record of the number of participants with events in the listed groups, alongside the recorded group sizes. They do not by themselves answer whether event rates differed reliably between treatments, whether events were related to RO7565020, or how findings apply beyond the participants and cohorts recorded. Those questions require details and analyses not reported in the registry record.
9. Statistical Methods Explained
The registry presents the primary safety outcome as a count of participants with AEs and SAEs. This is a binary participant-level outcome for each event category: a participant is counted as affected or not affected in that category. In general, a count is easiest to interpret alongside its denominator, because the same count can represent different proportions in differently sized groups. The adverse-event record gives participants at risk and participants affected for each listed group, so the counts can be read in their group context without inferring a treatment comparison.
What does a participant count capture?
A participant count records whether each participant met the outcome definition at least once during the specified observation period. It does not necessarily equal the total number of events. For example, multiple events in one participant could still contribute one participant to the affected count. Event-level frequency, recurrence, duration, timing, severity classification for non-serious events, and attribution to treatment are not reported in the registry record for this outcome.
The distinction between AEs and SAEs is also important. The AE definition is broad and includes medical occurrences that may not be related to treatment. SAE status is based on the stated seriousness criteria, including outcomes such as hospitalization or life-threatening events and other medically significant circumstances. Neither label alone establishes causation. The posted counts should not be interpreted as counts of confirmed drug reactions.
Why is the population definition important?
The primary endpoint’s safety population includes all participants randomized or assigned to study treatment who received at least one dose. Participants remain included under this definition even if they withdrew prematurely. This rule focuses the safety analysis on participants exposed to study treatment. The record does not report the number of participants who withdrew, the amount of follow-up completed by each participant, or whether any participants had incomplete safety information.
The registry lists an enrollment of 60, but that figure should not be substituted for each endpoint denominator. The adverse-event listing gives its own group-level at-risk counts. The record does not establish that the enrollment figure is the number treated or the number contributing to the primary safety population. In general, a transparent analysis distinguishes enrollment, treatment exposure, and the population contributing to a particular endpoint.
What does the study design contribute?
Randomization is a design method intended, in general, to allocate participants to groups by chance and reduce systematic differences between groups at the outset. Double masking is intended, in general, to limit the influence of treatment knowledge on participant behavior and outcome assessment. The registry labels the trial randomized and double-masked, but detailed procedures for allocation and masking are not reported in the registry record. The sequential, dose-finding and dose-escalation description indicates a cohort-based development approach; the cohort-specific dose sequence and decision rules are not reported.
For a sequential early-phase study, descriptive safety counts can help characterize what was observed in each cohort. General statistical caution is needed when comparing small cohorts: counts may vary substantially because of a small number of participants, and the groups may represent different stages or dosing contexts. The record does not specify cohort doses, so a pattern across cohort labels cannot be interpreted as a dose-response pattern from these counts alone.
What statistical comparisons are available?
The primary endpoint has not been reduced in the registry record to one comparison because it involves several categories or time points. No analysis records are listed, and no inferential results such as confidence intervals, p-values, or adjusted estimates are reported. A confidence interval, in general, is a range of values compatible with the data under a specified statistical procedure; it communicates uncertainty around an estimate rather than proving that a result is true. No such interval is available for the primary endpoint in the registry record.
In general, an inferential comparison would need a clearly specified outcome, comparison groups, analysis population, and method. For binary participant outcomes, methods can compare proportions or model the probability of an event, but the appropriate choice depends on the design, event frequency, and analysis objective. The registry record does not report a statistical analysis plan or an inferential method for the primary safety endpoint, so no particular method should be attributed to the study.
How should planning illustrations be viewed?
The record describes planning illustrations based on an observed effect, using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the target effect is described as a fraction of the observed effect. These are planning assumptions, not a report of the trial’s original design justification. The record does not report the study’s own sample-size justification. Any planning sample sizes are hypothetical illustrations, not observed power and not a measure of the probability that this study found an effect.
For time-to-event outcomes, the stated illustration convention is a total number of events; for other outcomes, it is participants per arm. This primary endpoint is reported as participants with events, but the posted record does not provide a single comparison or a sample-size illustration result for it. A planned sample size cannot replace an analysis of observed outcomes, and it does not supply missing uncertainty estimates.
Pharmacokinetic outcomes are listed separately, including maximum concentration, time to maximum concentration, exposure measures, terminal half-life, volume of distribution, and clearance. In general, these measures describe concentration over time and drug disposition. Their names indicate the intended measurements, but no numerical pharmacokinetic results or statistical analyses are reported in the registry record. The same applies to pharmacodynamic findings.
10. Multiplicity, Missing Data and Analysis Populations
The record lists multiple outcomes, including a primary safety endpoint and secondary pharmacokinetic measures. It also distinguishes outcome measures by study part and, for some measures, by route or cohort. When several outcomes, categories, or time points are examined, multiplicity is a general statistical concern: the more questions assessed, the greater the chance that some apparently notable finding may arise by chance if many tests are conducted. Whether and how to address that concern depends on the prespecified analysis plan and the role of each outcome.
A multiplicity adjustment, testing hierarchy, or other strategy for interpreting multiple comparisons is not reported in the registry record. The primary endpoint is not reduced to one comparison because it has several categories or time points. No inferential analyses are listed, so the record does not show a collection of tests whose results could be evaluated for multiplicity or identify whether any adjustment was used.
Missing-data handling is also not reported in the registry record. The safety population includes participants who received at least one dose, whether or not they withdrew early, but that definition does not explain how incomplete follow-up or missing event information was handled. The record does not state whether missing observations were imputed, excluded from a particular calculation, or treated by another rule. It also does not report the amount or pattern of missing data.
The defined safety population is distinct from an intention-to-treat population that might include all randomized participants regardless of treatment exposure; the registry’s stated definition requires at least one dose. The number randomized, number treated, and number included in each analysis are not reported in the registry record. These gaps limit assessment of whether the posted group counts cover all participants eligible under the stated definition.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Part 1a Placebo | 0 | 12 | 0.0% |
| Part 1a Cohort 1 | 0 | 6 | 0.0% |
| Part 1a Cohort 2 | 0 | 6 | 0.0% |
| Part 1a Cohort 3 | 0 | 6 | 0.0% |
| Part 1a Cohort 4 | 1 | 6 | 16.7% |
| Part 1a Cohort 5 | 0 | 6 | 0.0% |
| Part 1a Cohort 6 | 0 | 6 | 0.0% |
| Part 2a Cohort 1 | 0 | 6 | 0.0% |
| Part 2a Cohort 2 | 0 | 6 | 0.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Part 1a Placebo | 0 of 12 |
| Part 1a Cohort 1 | 0 of 6 |
| Part 1a Cohort 2 | 0 of 6 |
| Part 1a Cohort 3 | 0 of 6 |
| Part 1a Cohort 4 | 0 of 6 |
| Part 1a Cohort 5 | 0 of 6 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Part 1a Placebo | 6 of 12 |
| Part 1a Cohort 1 | 4 of 6 |
| Part 1a Cohort 2 | 5 of 6 |
| Part 1a Cohort 3 | 4 of 6 |
| Part 1a Cohort 4 | 6 of 6 |
| Part 1a Cohort 5 | 6 of 6 |
Most frequent serious adverse event terms
| Event term | Organ system | Part 1a Placebo | Part 1a Cohort 1 | Part 1a Cohort 2 | Part 1a Cohort 3 | Part 1a Cohort 4 | Part 1a Cohort 5 |
|---|---|---|---|---|---|---|---|
| Abdominal pain | Gastrointestinal disorders | 0 of 12 | 0 of 6 | 0 of 6 | 0 of 6 | 1 of 6 | 0 of 6 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Part 1a Placebo | Part 1a Cohort 1 | Part 1a Cohort 2 | Part 1a Cohort 3 | Part 1a Cohort 4 | Part 1a Cohort 5 |
|---|---|---|---|---|---|---|---|
| COVID-19 | Infections and infestations | 2 of 12 | 1 of 6 | 2 of 6 | 1 of 6 | 3 of 6 | 1 of 6 |
| Upper respiratory tract infection | Infections and infestations | 1 of 12 | 1 of 6 | 0 of 6 | 0 of 6 | 2 of 6 | 3 of 6 |
| Headache | Nervous system disorders | 0 of 12 | 2 of 6 | 1 of 6 | 1 of 6 | 2 of 6 | 0 of 6 |
| Back pain | Musculoskeletal and connective tissue disorders | 1 of 12 | 1 of 6 | 1 of 6 | 1 of 6 | 1 of 6 | 0 of 6 |
| Arthropod bite | Injury, poisoning and procedural complications | 2 of 12 | 0 of 6 | 0 of 6 | 0 of 6 | 0 of 6 | 1 of 6 |
| Bronchitis | Infections and infestations | 0 of 12 | 0 of 6 | 1 of 6 | 0 of 6 | 0 of 6 | 1 of 6 |
| Oral herpes | Infections and infestations | 0 of 12 | 0 of 6 | 1 of 6 | 0 of 6 | 0 of 6 | 1 of 6 |
| Viral upper respiratory tract infection | Infections and infestations | 0 of 12 | 0 of 6 | 1 of 6 | 0 of 6 | 0 of 6 | 1 of 6 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 1 of 12 | 0 of 6 | 0 of 6 | 0 of 6 | 1 of 6 | 0 of 6 |
| Migraine | Nervous system disorders | 1 of 12 | 0 of 6 | 0 of 6 | 0 of 6 | 0 of 6 | 1 of 6 |
Serious events with the highest arm-level rate: abdominal pain (16.7%).
The SAE figures are participant counts paired with the number at risk in each listed group. In Part 1a, placebo and Cohorts 1, 2, 3, 5, and 6 each list 0 participants affected by an SAE. Cohort 4 lists 1 participant affected by an SAE among 6 at risk. In Part 2a, Cohorts 1 and 2 each list 0 participants affected by an SAE among 6 at risk. No deaths are listed for any group.
The record lists abdominal pain as the top serious term, with 16.7%. That entry should be read as the registry’s reported term and percentage; the record does not provide further detail on event timing, treatment attribution, severity beyond serious status, or the affected participant’s cohort. The event term does not establish that RO7565020 caused the event.
Zero SAE-affected participants in a group means no participants were recorded with an SAE in that group in this listing. It does not establish that the underlying risk is zero. In general, estimates from small groups are uncertain, and the registry record does not give confidence intervals or comparative tests for these counts. SAE and other-AE counts are separate categories in the listing; they should not be combined into a newly calculated total. The posted figures describe recorded safety events, not a causal or comparative conclusion.
12. What the Result Does, and Does Not, Mean
The results establish that the registry lists participant-level AE and SAE counts for the named groups. In Part 1a, the listed number affected by other AEs ranges from 1 in Cohort 6 to 6 in Cohorts 4 and 5, while the placebo group lists 6. For SAEs, the listing shows 1 affected participant in Part 1a Cohort 4 and 0 in the other listed groups. The Part 2a groups list 2 and 3 participants affected by other AEs, respectively, and 0 affected by SAEs in each. No deaths are listed.
These data do not establish whether RO7565020 caused an event. The AE definition includes occurrences regardless of whether they are considered related to treatment, and the record does not provide participant-level causal assessments. The figures also do not show whether groups differ statistically: no inferential analysis, confidence interval, or p-value is reported for the primary safety endpoint. Small cohort counts and missing cohort-specific treatment details further limit comparisons.
The record does not establish that the drug is safe or unsafe in a broader population, nor does it establish efficacy. The study is described as Phase I and its stated purposes include safety, tolerability, pharmacokinetics, and pharmacodynamics. The posted adverse-event counts address only a descriptive part of that scope. No numerical pharmacokinetic or pharmacodynamic findings are reported in the registry record, and no clinical efficacy outcome is described in the registry entries.
Termination is a study status, not an explanation of why the study stopped or a result about treatment. The reason for termination is not reported in the registry record. Likewise, enrollment of 60 should not be interpreted as the number treated or analyzed without participant-flow information. The results support only a narrow reading: the listed number of participants with recorded events in each group, using the registry’s stated categories and denominators.
In general, a treatment effect requires a suitable comparison and an analysis that accounts for the design and uncertainty. The registry record does not report such an analysis for this endpoint. The descriptive counts are therefore useful for understanding what was recorded in these groups, but they are not a substitute for comparative estimates, detailed event narratives, or complete safety follow-up information.
13. Why This Trial Matters Statistically
This study matters statistically because early-phase dose-finding research asks questions that differ from those in a large confirmatory trial. The registry describes a first-in-human, sequential study intended to examine safety and tolerability and characterize pharmacokinetics and pharmacodynamics. In that setting, cohort-specific descriptions can be informative about the events recorded during exposure, while the design may not support a precise treatment comparison from the posted counts alone.
The record also illustrates why endpoint definitions and analysis populations need to be read together. The primary endpoint concerns healthy volunteers in Part 1a, is measured over up to approximately 40 weeks, and counts participants with AEs and SAEs. The adverse-event listing includes additional groups from Part 2a. Keeping those scopes distinct prevents results for different study parts from being treated as one primary comparison without justification.
Another important point is the difference between a count and an estimate of comparative effect. Counts show how many participants were recorded with events. Without an inferential analysis and an uncertainty measure, they do not establish whether a difference between groups is larger than would be expected from random variation. This distinction matters especially when groups contain few participants and details of cohort treatment assignments are not reported.
Finally, the registry’s lack of a reported analysis plan, missing-data approach, and reason for termination constrains independent interpretation. Those omissions do not invalidate the descriptive counts, but they limit the statistical questions that can be answered. The record is most informative when treated as a bounded account of reported safety observations rather than as a complete comparative evaluation of the investigational drug.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The primary limitation is that the registry does not report a single inferential comparison for the primary endpoint. It identifies several categories or time points and does not reduce them to one comparison; no analysis records are listed. Consequently, no comparative estimate, confidence interval, or p-value can be described from the posted results.
Group-level treatment details are incomplete. The registry lists RO7565020, placebo, and nucleos(t)ide analogue treatment, and names Part 1a and Part 2a cohorts, but the arm descriptions are empty. Cohort-specific doses, assignment details, and the role of nucleos(t)ide analogue treatment are not reported in the registry record. This prevents interpreting group patterns in relation to a specified dose or regimen.
The safety counts are limited to participant-level affected counts. The registry does not provide event-level totals, participant narratives, timing, duration, severity details for non-serious events, or causal assessments. It also does not report follow-up completeness or how incomplete safety data were handled. The stated safety population definition is useful, but participant flow into that population is not reported.
The record lists enrollment of 60, but does not establish how many participants were randomized, treated, or analyzed in each group. Small listed group sizes limit the precision of descriptive comparisons. The sample-size planning assumptions are not the trial’s own design justification, and the reason the study was terminated is not reported in the registry record.
Finally, although pharmacokinetic and pharmacodynamic measures are listed as objectives and secondary outcomes, their numerical results are not reported in the registry entries. These limitations mean that interpretation must remain confined to the reported group counts and study description, without attributing causes or extrapolating beyond the listed participants.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection — NCT05763576.
- Registry record last updated 2026-01-22; status last verified 2026-01.
- Results first posted 2026-01-22.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
The registry describes NCT05763576 as a randomized, double-masked, sequential Phase I study of RO7565020 in healthy participants and participants with chronic hepatitis B virus infection. It was intended as a first-in-human dose-finding and dose-escalation study of safety, tolerability, pharmacokinetics, and pharmacodynamics. The registry lists enrollment of 60, status as terminated, a start date of 2023-04-28, and a primary completion date of 2024-12-23.
The primary endpoint counts healthy volunteers in Part 1a with adverse events and serious adverse events over up to approximately 40 weeks. The posted group listings include Parts 1a and 2a, with participant counts affected by each event category and no deaths listed. The registry does not report a single inferential comparison, statistical analysis results, or numerical pharmacokinetic and pharmacodynamic findings. The reason for termination and detailed cohort treatment assignments are not reported in the registry record.